Founded in 1849 and with headquarters in New York City, USA, Pfizer, a global pharmaceutical company is ranked 4th in the list of top 10 pharmaceutical companies in the world and has annual revenue of $48.851 billion, R & D expenditure of $7.69 billion and a basic EPS of $1.13.
Pfizer has an employee count of about 78300 and is ranked 51 in the Fortune Global 500 Companies list, 2015. Pfizer had classified its offerings into two business segments: Innovative Products Business and Established Products Business.
Under the Innovative Products Business, Global Innovative Pharmaceutical (GIP) segment with drugs in spaces like cardio-metabolic, immunology, neuroscience and rare diseases contributed to 28.6% of overall annual revenue and the Global Vaccines, Oncology and Consumer Healthcare (VOC) segment with vaccines like Prevnar contributed to 26.2% of annual revenue.
Some popular consumer products made by the company are:
The Established Products Business contributed to 44.2% of annual revenue with branded generics, sterile injectable products, biosimilars and infusion systems in its portfolio. Pfizer believes in expanding its offerings through acquisitions as well and this can be seen from the announcement made by Pfizer in May 2016 regarding the acquisition of Anacor in a $5.2 billion deal.